Latest International Markets News

Ionic Rare Earths has secured a listing on the U.S. OTCQB Venture Market, enhancing access for American investors to its rare earth and magnet recycling ventures. This move aligns the company with North American critical minerals priorities and broadens its global investor base.

Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Love Group Global Ltd has reported record operating profits in Q2 FY26, driven by growth in Hong Kong and marketing efficiencies, while planning to expand its matchmaking services into new international markets.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

BPH Global reported a seasonal dip in December revenue due to rainy conditions affecting seaweed supply, yet maintains strong growth momentum with A$1.77 million gross revenue over seven months.